Dec 28 (Reuters) - Some U.S. stocks on the move on Friday:
WALL ST OPENS DOWN BEFORE TALKS ON ‘CLIFF’ DEAL
U.S. stocks fell at the open as President Barack Obama and top lawmakers planned to make a last-ditch attempt at a budget deal to prevent the United States from going over the “fiscal cliff.” The Dow Jones industrial average was down 0.58 percent, the Standard & Poor’s 500 Index down 0.63 percent and the Nasdaq Composite Index down 0.67 percent.
** AETERNA ZENTARIS INC, $2.45, up 13 pct (0940 ET)
The drugmaker said the design, main goals and analysis of a late-stage study of its endometrial cancer drug was accepted by the U.S. health regulator to support an application for marketing approval.
** MAGICJACK VOCALTEC LTD, $17.18, up 5.5 pct (0957 ET)
The Israel-based company, which makes devices that enable voice telephony over the Internet, raised its operating income forecast to more than 70 cents per share in the fourth quarter from more than 50 cents, on lower costs.
The company also named Gerald Vento as chief executive, effective Jan. 1.
** CENTRAL EUROPEAN DISTRIBUTION CORP, $2.03, down 7 pct (1133 ET)
The vodka maker agreed to cede operational control to top shareholder Roustam Tariko, in return for access to funding of up to $65 million from him.
** TOWER INTERNATIONAL INC $7.96, up 7 pct (0934 ET)
The automobile parts maker sold its South Korean operations to Seco, a privately owned Korean auto parts supplier, for about $47 million in cash.
** MAGNUM HUNTER RESOURCES CORP, $3.96, up 5 pct (0939 ET)
The oil and gas company reported production results from two new Eagle Ford Shale wells in Texas.
** BARNES & NOBLE INC, $15.59, up 8 pct (0953 ET)
British education and media publisher Pearson Plc said it would buy a 5 percent stake in Barnes & Noble’s digital Nook and college bookstore businesses for $89.5 million.
** OMEROS CORP, $5.58, down 4.5 pct (0939 ET)
The company said a late-stage trial of its experimental drug for patients undergoing knee surgery did not meet its main goal.
Canaccord Genuity and Deutsche Bank cut their price targets on the stock but maintained their “buy” ratings, saying they continued to believe the drug would gain U.S. health regulators’ approval.
** CEPHEID INC, $34.07, up 4 pct (0944 ET)
The company said late on Thursday that its molecular diagnostic test for detecting and differentiating between gonorrhea and chlamydia, two common sexually transmitted bacterial infections, was approved in the United States. Cepheid said it will begin shipping the test, Xpert CT/NG, in January. (Compiled by Avik Das in Bangalore)